share_log

健康元(600380.SH):TG-1000胶囊Ⅲ期临床试验达到主要终点

Health Source (600380.SH): TG-1000 capsule phase III clinical trial reached the main end

Gelonghui Finance ·  Apr 17 06:32

Gelonghui, April 17 | Health Source (600380.SH) announced that recently, the company's innovative drug product TG-1000 capsules for use in a multi-center phase III clinical trial (referred to as this study) with no complications in acute influenza A and B infections aged 12 and above (referred to as this study) reached the end of the main study. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment